MNKD MannKind Corporation

NASDAQ
$3.34

MannKind Corporation (MNKD) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.6% since its last earnings release on August 5, 2026.

MannKind Missed Consensus Estimates
Wednesday, August 5, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.08)
Rev est $105.56M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.86

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MannKind Corporation

MannKind Corp is a development stage company engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.